Pivotal single-dose bioavailability study of CCP-07

Trial Profile

Pivotal single-dose bioavailability study of CCP-07

Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs CCP 07 (Primary)
  • Indications Common cold
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Apr 2017 According to a Vernalis media release, the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-07. The CRL did not raise any concerns with the formulation or pharmacokinetic profile of CCP-07 but did identify outstanding items that need to be addressed prior to the resubmission and approval of the NDA. The company will be working closely with the FDA to resubmit the NDA as quickly as possible.
    • 01 Dec 2016 According to a Vernalis media release, is filing NDA with FDA with a PDUFA date of 20 April 2017.
    • 23 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top